Subungual keratoacanthoma: Analysis of cell proliferation and copy number variation of oncogenes compared with periungual squamous cell carcinoma

Clinical and Experimental Dermatology

Volumn 36, Issue 1, 2011, Pages 57-62

  Honma, M ^a   Kato, N ^a   Hashimoto, M ^a   Takahashi, H ^a   Ishida Yamamoto, A ^a   Iizuka, H ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEIN P50;

ADULT; AGED; ARTICLE; CASE REPORT; CELL PROLIFERATION; COPY NUMBER VARIATION; DISEASE MARKER; EPITHELIUM TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; SUBUNGUAL KERATOACANTHOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CORTACTIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; KERATOACANTHOMA; MALE; NAIL DISEASES; NF-KAPPA B P50 SUBUNIT; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ONCOGENES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650110449     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03841.x     Document Type: Article

References (25)

1. Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual keratoacanthoma with reossification of underlying distal lytic phalynx. Clin Exp Dermatol 2005; 30: 20-2.
2. Baran R, Goettmann S. Distal digital keratoacanthoma: a report of 12 cases and a review of the literature. Br J Dermatol 1998; 139: 512-15.
3. Oliwiecki S, Peachey RD, Bradfield JW et al. Subungual keratoacanthoma - a report of four cases and review of the literature. Clin Exp Dermatol 1994; 19: 230-5.
4. LeBoit PE. Can we understand keratoacanthoma? Am J Dermatopathol 2002; 24: 166-8.
5. Karaa A, Khachemoune A. Keratoacanthoma. A tumor in search of a classification. Int J Dermatol 2007; 46: 671-8.
6. Dobson CM, Azurdia RM, King CM. Squamous cell carcinoma arising in a psoriatic nail bed: case report with discussion of diagnostic difficulties and therapeutic options. Br J Dermatol 2002; 147: 144-9.
7. Skalova A, Michal M. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections. Am J Dermatopathol 1995; 17: 332-4.
8. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001; 158: 1633-7.
9. Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005; 47: 170-8.
10. Papadavid E, Pignatelli M, Zakynthinos S et al. The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma. Br J Dermatol 2001; 145: 582-9.
11. Cain CT, Niemann TH, Argenyi ZB. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors. Am J Dermatopathol 1995; 17: 324-31.
12. Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol 1991; 127: 1167-71.
13. Kirkham N. Keratoacanthoma. In: Lever's Histopathology of the Skin, 8th edn (Elder D, Elenitsas R, Jaworsky C, Johnson B, eds). Philadelphia: Lippincott-Raven, 1997; 731-4.
14. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130: 181-6.
15. Takata M, Suzuki T, Ansai S et al. Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): its usefulness as an adjunctive diagnostic tool for melanocytic tumors. J Dermatol Sci 2005; 40: 51-7.
16. Perez-Moreno M, Davis MA, Wong E et al. p120-catenin mediates inflammatory responses in the skin. Cell 2006; 124: 631-44.
17. Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 2002; 188: 103-7.
18. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22: 1387-98.
19. Luo ML, Shen XM, Zhang Y et al. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 2006; 66: 11690-9.
20. Ahmed NU, Ueda M, Ichihashi M. Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma. Br J Dermatol 1997; 136: 908-12.
21. Murre C. Intertwining proteins in thymocyte development and cancer. Nat Immunol 2000; 1: 97-8.
22. Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006; 12: 4499-505.
23. Ma S, Guan XY, Beh PS et al. The significance of LMO2 expression in the progression of prostate cancer. J Pathol 2007; 211: 278-85.
24. Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol 2003; 170: 5697-703.
25. Fribley AM, Evenchik B, Zeng Q et al. Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 2006; 281: 31440-7.